顯影劑市場規模、佔有率和成長分析（按類型、影像方式、給藥途徑、應用、最終用戶和地區）- 2025-2032 年產業預測

2023 年顯影劑造影劑市場規模價值為 54 億美元，預計將從 2024 年的 55.6 億美元成長到 2032 年的 70.5 億美元，預測期內（2025-2032 年）的複合年成長率為 3.0%。

複雜合併症和慢性病的增加導致超音波、X光、核磁共振和電腦斷層掃描等診斷影像程序的顯著增加。 2022年9月，美國FDA核准了具有高相對率、減少钆劑量特徵的新型MRI顯影劑钆皮醇，這是一個重要的里程碑。這項進步不僅能提高成像精度，還能增強成人和 2 歲及以上兒童的病患安全性。 Gadopiclenol 的配方滿足了日益成長的減輕傳統顯影劑相關風險的需求，代表了診斷成像技術發展的重要一步，並滿足了廣泛的醫療保健需求。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

顯影劑市場規模（按類型）

• 市場概況
• 碘顯影劑
• 钆基顯影劑
• 鋇基顯影劑
• 微氣泡顯影劑
• 其他

顯影劑市場規模（依影像診斷方法分類）

• 市場概況
• X光/CT
• MRI
• 超音波
• 其他

顯影劑市場規模（依給藥途徑分類）

• 市場概況
• 血管內
• 口腔/直腸
• 其他

顯影劑市場規模（依應用分類）

• 市場概況
• 心血管
• 神經系統疾病
• 癌症
• 胃腸道疾病
• 肌肉骨骼疾病
• 其他

顯影劑市場規模（依最終用戶分類）

• 市場概況
• 醫院
• 診斷影像中心
• 門診手術中心
• 其他

顯影劑市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Bayer AG（Germany）
• Bracco Imaging SpA（Italy）
• GE Healthcare（US）
• Guerbet（France）
• Lantheus Medical Imaging, Inc.（US）
• NanoPET Pharma GmbH（Germany）
• Fujifilm Corporation（Japan）
• Beijing Beilu Pharmaceutical Co. Ltd.（China）
• Taejoon Pharm Co. Ltd.（South Korea）
• Jubilant Life Sciences Ltd.（India）
• Siemens Healthineers（Germany）
• Philips Healthcare（Netherlands）
• Cardinal Health（US）
• McDermott International（US）
• Medtronic（Ireland）
• Terumo Corporation（Japan）
• Abbott Laboratories（US）
• Baxter International（US）
• Fresenius Medical Care AG & Co. KGaA（Germany）
• Novartis AG（Switzerland）

結論和建議

Contrast Agents Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 7.05 billion by 2032, growing at a CAGR of 3.0% during the forecast period (2025-2032).

The increasing prevalence of complex comorbidities and chronic conditions is driving a notable rise in diagnostic imaging procedures, including ultrasounds, X-rays, MRIs, and CT scans. A key milestone was achieved in September 2022 when the U.S. FDA approved Gadopiclenol, a novel MRI contrast agent characterized by high relativity and a reduced gadolinium dosage. This advancement enhances imaging precision while ensuring heightened patient safety for both adults and children aged two years and above. Gadopiclenol's formulation addresses the growing need to mitigate risks linked to traditional contrast agents, indicating a significant step forward in the evolution of diagnostic imaging technology and catering to a wide array of healthcare requirements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Contrast Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Contrast Agents Market Segments Analysis

Global Contrast Agents Market is segmented by Type, Imaging Modality, Route of Administration, Application, End User and region. Based on Type, the market is segmented into Iodinated Contrast Agents, Gadolinium-Based Contrast Agents, Barium-Based Contrast Agents, Microbubble Contrast Agents and Others. Based on Imaging Modality, the market is segmented into X-Ray/CT, MRI, Ultrasound and Others. Based on Route of Administration, the market is segmented into Intravascular, Oral/Rectal and Others. Based on Application, the market is segmented into Cardiovascular, Neurological Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders and Others. Based on End User, the market is segmented into Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Contrast Agents Market

The growing acceptance of image-guided surgeries (IGS) represents a pivotal trend within the medical field. As these procedures gain popularity, they play a crucial role in both diagnosing and treating a wide range of medical conditions. This rising demand for accurate, real-time imaging improvements during surgical procedures highlights the need for innovative techniques in data acquisition, processing, and display. Additionally, there is an increasing emphasis on understanding imaging processes and their clinical applications. This landscape creates a significant opportunity for advancements in contrast agents that enhance visualization and precision in image-guided surgical practices.

Restraints in the Contrast Agents Market

The Contrast Agents market faces certain impediments, despite advancements in medical technology and the development of improved contrast agent formulations. A portion of patients still experiences side effects or allergic reactions related to these agents. Although these adverse reactions are relatively infrequent, they can vary in severity, from mild discomfort to critical conditions that require urgent medical intervention. Common symptoms include skin reactions, nausea, and shortness of breath; in rare instances, they can escalate to more serious concerns, such as anaphylaxis. These potential health risks place constraints on the widespread adoption of contrast agents in medical procedures.

Market Trends of the Contrast Agents Market

The Contrast Agents market is poised for significant growth, driven by the increasing prevalence of multiple chronic conditions among the aging population. As nearly 80% of individuals aged 65 and older suffer from at least one chronic ailment, the demand for advanced imaging techniques, facilitated by contrast agents, is surging. This demographic shift, projected to see 77 million seniors in the U.S. by 2034, highlights the urgent need for enhanced diagnostics to address the complexities of managing multiple comorbidities. Consequently, the demand for innovative contrast agents is expected to rise sharply, creating lucrative opportunities for key players in the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Contrast Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Iodinated Contrast Agents
• Gadolinium-Based Contrast Agents
• Barium-Based Contrast Agents
• Microbubble Contrast Agents
• Others

Global Contrast Agents Market Size by Imaging Modality & CAGR (2025-2032)

• Market Overview
• X-Ray/CT
• MRI
• Ultrasound
• Others

Global Contrast Agents Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravascular
• Oral/Rectal
• Others

Global Contrast Agents Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cardiovascular
• Neurological Disorders
• Cancer
• Gastrointestinal Disorders
• Musculoskeletal Disorders
• Others

Global Contrast Agents Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers
• Others

Global Contrast Agents Market Size & CAGR (2025-2032)

• North America (Type, Imaging Modality, Route of Administration, Application, End User)
  • US
  • Canada
• Europe (Type, Imaging Modality, Route of Administration, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Imaging Modality, Route of Administration, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Imaging Modality, Route of Administration, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Imaging Modality, Route of Administration, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging SpA (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoPET Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Beilu Pharmaceutical Co. Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taejoon Pharm Co. Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Life Sciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McDermott International (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations